NCI-H526細(xì)胞

器官來(lái)源： 肺

運(yùn)輸方式： 凍存運(yùn)輸

是否是腫瘤細(xì)胞： 1

物種來(lái)源： 人

細(xì)胞形態(tài)： 上皮樣

年限： stage E

數(shù)量： 大量

生長(zhǎng)狀態(tài)： 懸浮生長(zhǎng)

ATCC Number： CRL-5811?

相關(guān)**： 其他**

NCI-H526細(xì)胞Designations: NCI-H526 [H526]

Depositors: AF Gazdar, JD Minna

Biosafety Level: 1

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: round clusters in suspension

Organism: Homo sapiens

Morphology: epithelial

Source: Organ: lung

Tumor Stage: stage E

Disease: carcinoma; variant small cell lung cancer

Derived from metastatic site: bone marrow

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Restrictions: NCI-H526細(xì)胞The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. A. Gazdar and Dr. J. Minna and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 699-8056, FAX (214) 688-7233.

Receptors: insulin-like growth factor II (IGF II); bombesin

Tumorigenic: Yes

Oncogene: myc +; myb +; fes +; fms +; raf +; ras +

DNA Profile (STR): Amelogenin: X,Y

CSF1PO: 11

D13S317: 13

D16S539: 9

D5S818: 11

D7S820: 9,12

THO1: 6,8

TPOX: 8,11

vWA: 16,17

Age: 55 years *****

Gender: male

Ethnicity: Caucasian

Comments: NCI-H526細(xì)胞This line was derived by A.F. Gazdar, H.K. Oie, J.D. Minna and associates from a bone marrow metastasis taken from a patient prior to therapy.

NCI-H526 expresses elevated levels of 2 biochemical markers of SCLC: neuron specific enolase and the brain isoenzyme of creatine kinase.

They do not express L-dopa carboxylase or bombesin-like immunoreactivity.

These cells express the c-kit gene as well as the N-myc gene, but not c-myc or L-myc.

N-myc is amplified and p75 c-myb expression was observed.

NCI-H526 also expresses the proto-oncogenes N-ras, Ki-ras, Ha-ras, and c-raf1.

Only trace amounts of the retinoblastoma susceptibility gene, RB mRNA were detected.

RB protein was not detected.

The cells express easily detectable levels of p53 mRNA compared to levels found in normal lung.

Abnormally sized mRNA was present.

The line has a reported colony-forming efficiency of 4.2% in soft agarose.

Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.

Temperature: 37.0°C

Subculturing: Medium Renewal: Every 2 to 3 days

Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation of the suspension with subsequent resuspension in fresh medium. Add medium as the cell density increases.

Preservation: NCI-H526細(xì)胞Culture medium, 95%; DMSO, 5%

Doubling Time: 36 hrs

Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001

recommended serum:ATCC 30-2020

purified DNA:ATCC CRL-5811D

References: 1806: Takahashi T, et al. p53: A frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989. PubMed: 2554494

22250: Bepler G, et al. Expression of p64c-myc and neuroendocrine properties define three subclasses of small cell lung cancer. Oncogene 4: 45-50, 1989. PubMed: 2536917

22446: Schardt C, et al. Characterization of insulin-like growth factor II receptors in human small cell lung cancer cell lines. Exp. Cell Res. 204: 22-29, 1993. PubMed: 8380141

22725: Lai SL, et al. Molecular genetic characterization of neuroendocrine lung cancer cell lines. Anticancer Res. 15: 225-232, 1995. PubMed: 7762988

23056: Carney DN, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 45: 2913-2923, 1985. PubMed: 2985257

23065: Kiefer PE, et al. Amplification and expression of protooncogenes in human small cell lung cancer cell lines. Cancer Res. 47: 6236-6242, 1987. PubMed: 2824028

23080: Hensel CH, et al. Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res. 50: 3067-3072, 1990. PubMed: 2159370

23104: Ohsaki Y, et al. Human small cell lung cancer cell lines express functional atrial natriuretic peptide receptors. Cancer Res. 53: 3165-3171, 1993. PubMed: 8391389

23106: Plummer H, et al. c-myc expression correlates with suppression of c-kit protooncogene expression in small cell lung cancer cell lines. Cancer Res. 53: 4337-4342, 1993. PubMed: 7689933

23162: Verbeeck MA, et al. Expression of the vasopressin and gastrin-releasing peptide genes in small cell lung carcinoma cell lines. Pathobiology 60: 136-142, 1992. PubMed: 1320893

23227: Johnson BE, et al. Retention of chromosome 3 in extrapulmonary small cell cancer shown by molecular and cytogenetic studies. J. Natl. Cancer Inst. 81: 1223-1228, 1989. PubMed: 2569043

23386: Bepler G, et al. Substance P analogues function as bombesin receptor antagonists and inhibit small cell lung cancer clonal growth. Peptides 9: 1367-1372, 1988. PubMed: 2470067

23570: . NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996..

24389: . . Lung Cancer 4: 155-161, 1988.